Oncology

New agents can offer a more tailored approach to therapy selection.

Selpercatinib is an oral selective RET kinase inhibitor approved for the treatment of metastatic RET fusion-positive non-small cell lung cancer and for metastatic thyroid cancer.

In a trial, sacituzumab govitecan-hziy demonstrated a 34% reduction in the risk of disease progression or death compared with physician’s choice chemotherapy.

Rucaparib is the only PARP inhibitor demonstrated to have better outcomes than a docetaxel-containing control arm, according to researchers.

For patients facing end-of-life care, psychedelic medicines may offer a chance to feel connected with themselves and others during such a difficult time.

Researchers identified a new immunotherapeutic target that may be effectively treated with CAR T-cell therapy in patients with pretreated multiple myeloma.

Results from the largest head-to-head trial of programmed death receptor-1 inhibitors suggest that dostarlimab and chemotherapy could be an effective treatment option for patients with metastatic non-squamous non-small cell lung cancer.

Higher C-reactive protein levels have been linked to cognition problems among older breast cancer survivors.

Two Houston Methodist cancer researchers were granted a quarter-million dollars each to study some of the most lethal forms cancer, including triple-negative breast cancer and multiple myeloma.

Currently available agents may reduce the need for stem cell transplantation in patients with acute lymphocytic leukemia.

Relapses remain a challenge in treating patients with leukemia.

The FDA approved the only companion diagnostic that is indicated to assess low levels of HER2 proteins in patients with metastatic breast cancer.

Two recent clinical trials highlight the novel therapy options available to patients in the upfront and relapsed settings.

An integrative efficacy score would incorporate the depth, duration, and prevalence of tumor response.

Mosunetuzumab showed promising results in complete response rate in patients with follicular lymphoma.

Futibatinib (Lytgobi, Taiho Oncology, Inc) is indicated for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements.

Oncology pharmacists participate significantly in conversations, research, and publications of that research.

Pharmacy Times will be spotlighting pharmacists throughout the month of October to recognize their contributions to the health care field.

October is Breast Cancer Awareness Month.

Biology and disease type may help determine which therapeutic options could work best for patients with Waldenstrom macroglobulinemia.

Study results show that the frequency of adverse events decreased after the patients transitioned from combination therapy to monotherapy.

New research in immunotherapy is exploring vaccines to treat cancer, whether preventative or reactive against current tumors.

Belantamab mafodotin plus lenalidomide and dexamethasone was found tolerable with no new safety signals and enhanced response rates in patients with multiple myeloma.

All of the findings indicate that inadequate margin widths result in higher risks of distant recurrence and breast cancer mortality, as well as increased total recurrence.

Ivosidenib plus azacitidine shows benefits in event-free survival, overall survival, and clinical responses compared with placebo in patients with IDH1-mutated acute myeloid leukemia.

The functional and physical well-being and other scores from the survey are more favorable for those who were treated with the therapy, investigators say.

A researcher discusses how developing tertiary lymphoid structures may reach a greater maturity level within the tumor microenvironment.

Given that dendritic cells are necessary for anti-tumor response, researchers investigated which pathways stop these cells from performing their full functions.